SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biomatrix (BXM) Looking Great -- Ignore unavailable to you. Want to Upgrade?


To: James Baker who wrote (407)2/26/1998 6:42:00 AM
From: John McCarthy  Read Replies (1) | Respond to of 569
 
James -

Orthovisc *is* a year off.

The O/A target market for Synvisc/Orthovisc is * I think *
about 7,000,000 out of a 16,000,000 total market.

This is my estimate of Stage I , II , III O/A.

At just *275,000* 1st time users, BIOX gross sales are roughly
$48,000,000. And at *just* 550,000 1st time users BIOX
gross sales are at $96,000,000.

IOW, the potential market is so big, that competition HELPS
get the word out. Helps get more potential customers trying
it quicker. And forces AHP to keep on top of things.

Regards

John